Dr. Simon Ekman graduated as
M.D. from Uppsala University, Sweden, in 2004. He completed his training in Medical
Oncology and Radiotherapy in 2009 at the Department of Oncology, Uppsala
University Hospital.
He obtained his Ph.D. in Molecular Cell Biology
in 2000 at the Ludwig Institute for Cancer Research, Uppsala University, and
was a postdoctoral fellow at Uppsala University between 2002-2004.
His research focuses on thoracic oncology,
mainly lung cancer, and includes both clinical and preclinical studies. He has
been a supervisor of several Ph.D.-students and was the Director of Studies,
Department of Oncology, Uppsala University Medical School, 2006-2008.
He has been a clinical investigator for several
phase I, II and III studies in thoracic oncology and solid tumors and he is a
member of the Swedish National Board on Treatment of Lung Cancer, where he has
participated in the development of national treatment recommendations for lung
cancer. Dr. Ekman is a member of the International Association for the Study of
Lung Cancer (IASLC) and American Society of Clinical Oncology.
As a Visiting Research Fellow in the Biomarker
Analysis Laboratory for Lung Cancer Research of Dr. Fred Hirsch at the
University of Colorado Denver his research is focused on resistance mechanisms
in the treatment of lung cancer with EGFR targeted therapy. Novel targeted
agents and corresponding biomarkers for response are analyzed in this pursuit.